Active	Status	Sponsor type	Region	Phase	Filter
4 Active 6 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bechara, Falk G
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	Recruiting	2	350	Europe, Canada, US, RoW	Eltrekibart, LY3041658, Placebo	Eli Lilly and Company	Hidradenitis Suppurativa	08/25	07/26
OREA, NCT05131373: Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris	Completed	1	38	Europe	ORG101 - Experimental 1, ORG101PL - Placebo 1	Sanofi Pasteur, a Sanofi Company	Acne Vulgaris, Acne	11/23	11/23
NCT04944862: A Study of CDX-0159 in Patients With Prurigo Nodularis Nov 2023 - Nov 2023 : Topline data from trial for prurigo nodularis	Completed	1	24	Europe, US	CDX-0159, barzolvolimab, Normal saline	Celldex Therapeutics	Prurigo Nodularis	07/23	07/23
DEVISE, NCT06324695: Development and EValuation of an Online Intervention to Reduce Self-Stigma in People with Visible Chronic Skin DisEases	Active, not recruiting	N/A	298	Europe	HautKompass	Universitätsklinikum Hamburg-Eppendorf, German Federal Ministry of Education and Research	Psoriasis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Atopic Dermatitis	12/24	05/25